This clinical trial is focused on studying the effects of a medication called Forxiga, which contains the active ingredient dapagliflozin. The study is investigating its impact on a condition known as heart failure with preserved ejection fraction (HFpEF). This type of heart failure occurs when the heart muscle contracts normally but the ventricles do not relax as they should during heartbeats, leading to symptoms like shortness of breath and fatigue.

The purpose of the study is to understand how dapagliflozin can benefit patients with HFpEF. Participants in the study will take Forxiga in the form of film-coated tablets. The study will explore how the medication affects the heart’s function and structure over time. This includes looking at how the heart muscle relaxes and contracts, as well as changes in heart size and shape using imaging techniques like MRI and echocardiography. The study will also examine changes at the cellular level, such as heart muscle cell stiffness and the presence of certain proteins.

Throughout the study, participants will be monitored to see how their heart condition responds to the treatment. The study aims to provide insights into the biological and mechanical processes that contribute to the benefits of dapagliflozin in managing HFpEF. This research could help improve understanding and treatment of this type of heart failure in the future.